Cabaletta Bio Inc. (CABA)
CABA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | CABA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2019 |
| SEC CIK | 0001759138 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "As disclosed in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, the Company had previously identified conditions that raised substantial doubt about its ability to continue as a going concern." | 10-Q 2026-11-05 |
| Cash and burn | $299.4M cash; operating cash flow -$40.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 215,720,392 (2026-10-30); 96,265,204 a year earlier; 42,849,412 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-05-04 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Philadelphia, Pennsylvania, United States | PCAOB Form AP 2026-04-01 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $296K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$53.1M | -$42.7M | $299.4M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | Not filed | -$51.0M | -$41.5M | $225.1M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q1 2026 2026-03-31 | Not filed | -$43.5M | -$42.6M | $116.6M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2025 2025-12-31 | Not filed | -$41.9M | -$35.3M | $83.0M | No debt tags | Needs four quarters | 10-K 2026-03-23 |
| Q3 2025 2025-09-30 | Not filed | -$44.9M | -$34.5M | $60.2M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | Not filed | -$45.1M | -$30.4M | $145.6M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q1 2025 2025-03-31 | Not filed | -$35.9M | -$30.8M | $131.8M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2024 2024-12-31 | Not filed | -$32.6M | -$23.1M | $164.0M | No debt tags | Needs four quarters | 10-K 2026-03-23 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-05-04 |
| Latest annual report | 10-K | 2026-03-23 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-06-01 |
Source: SEC EDGAR submissions feed, 454 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.5% |
| 1 month | -24.3% |
| 3 months | -52.8% |
| Year to date | -41.6% |
| 1 year | -45.3% |
| From 52-week high | -69.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PLX | Protalix BioTherapeutics Inc. (DE) | $3.03 | -0.66% | $255.5M |
| OCGN | Ocugen Inc. | $0.7730 | -6.62% | $262.3M |
| LXEO | Lexeo Therapeutics Inc. | $3.23 | +12.54% | $265.0M |
| SABS | SAB Biotherapeutics Inc. | $3.00 | +1.35% | $270.3M |
| DTIL | Precision BioSciences Inc. | $7.28 | -3.77% | $277.6M |
| ALLO | Allogene Therapeutics Inc. | $0.8070 | -3.78% | $279.6M |
| IKT | Inhibikase Therapeutics Inc. | $1.45 | -4.61% | $203.4M |
| AGEN | Agenus Inc. | $6.29 | -6.54% | $284.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier